Key terms
About VRNA
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VRNA news
Apr 16
6:55am ET
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Apr 16
6:46am ET
Verona Pharma price target raised to $36 from $31 at Piper Sandler
Mar 08
7:56am ET
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy
Mar 01
7:35am ET
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Mar 01
7:06am ET
Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline
Mar 01
1:03am ET
Verona Pharma’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Feb 08
7:40am ET
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Verona Pharma (VRNA) and Molina Healthcare (MOH)
Feb 07
5:55am ET
Verona Pharma management to meet virtually with Piper Sandler
Feb 06
4:55am ET
Verona Pharma management to meet virtually with Piper Sandler
Jan 31
7:59am ET
Verona Pharma management to meet virtually with Piper Sandler
Jan 24
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Verona Pharma (VRNA), ACADIA Pharmaceuticals (ACAD)
No recent press releases are available for VRNA
VRNA Financials
Key terms
Ad Feedback
VRNA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VRNA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
